- |||||||||| Enrollment closed, Trial completion date, Trial primary completion date: Antiseizure Medication in Seizure Networks at Early Acute Brain Injury (clinicaltrials.gov) - Feb 12, 2025
P4, N=54, Active, not recruiting,
Recruiting --> Active, not recruiting | Trial completion date: Aug 2025 --> Apr 2025 | Trial primary completion date: May 2025 --> Jan 2025
- |||||||||| Review, Journal: Intravenous push administration of anti-seizure medications. (Pubmed Central) - Feb 11, 2025
This is important given the time-sensitive nature of status epilepticus treatment. This review will discuss several anti-seizure medications, including phenytoin, fosphenytoin, valproic acid, levetiracetam, brivaracetam and lacosamide, for which evidence supports the safe and efficacious use of IV push administration.
- |||||||||| levetiracetam / Generic mfg.
Journal: Association of interictal epileptiform discharges and serum concentration of levetiracetam and lamotrigine. (Pubmed Central) - Feb 10, 2025
Furthermore, our study highlights the importance of ASM discontinuation, which may be required for capturing IEDs during diagnostic continuous EEG monitoring, and not be fully explained by circadian or ultradian rhythms alone. Our findings contribute to the understanding of ASM effects on IED frequency dynamics and suggest seizure suppressive properties of LEV and LTG.
- |||||||||| Journal: Presence, removal, and risks of psychopharmaceuticals in wastewater streams. (Pubmed Central) - Feb 7, 2025
This study highlights that wastewater contains abundant numbers and ecotoxicologically relevant concentrations of psychopharmaceuticals that are insufficiently removed by the WWTP. The implementation of risk-based removal targets in legislation is discussed to facilitate the reduction in emissions of psychopharmaceuticals, for example, by adequate WWTP upgrades with advanced treatments to ensure a toxic-free environment.
- |||||||||| temozolomide / Generic mfg., levetiracetam / Generic mfg.
Review, Journal: Levetiracetam and valproic acid in glioma: antiseizure and potential antineoplastic effects. (Pubmed Central) - Feb 6, 2025
This extended survival, if one exists, may be only observed in certain gliomas with corresponding patient characteristics. We provide a brief overview of the management of BTRE, VPA and LEV as anticonvulsants and antineoplastics, and the factors that may be associated with survival in epileptogenic glioma.
- |||||||||| levetiracetam / Generic mfg.
Trial completion date, Trial primary completion date: STING: Seizure Treatment in Glioma (clinicaltrials.gov) - Feb 4, 2025
P4, N=120, Recruiting,
The treatment of an acute attack of HAE should focus on replacing C1-INH and preventing the formation and limiting the action of bradykinin. Trial completion date: Jan 2028 --> Jul 2028 | Trial primary completion date: Jan 2026 --> Jul 2026
- |||||||||| Review, Journal: Update on Antiseizure Medications 2025. (Pubmed Central) - Feb 3, 2025
Since the most recent version of this article was published, one new antiseizure medication, ganaxolone, has been approved by the US Food and Drug Administration (FDA), and the indications of some approved medications were expanded...These agents include lamotrigine, oxcarbazepine, levetiracetam, topiramate, zonisamide, and lacosamide...Lacosamide, pregabalin, and eslicarbazepine have undergone successful trials of conversion to monotherapy for focal epilepsy...Knowledge of antiseizure medication pharmacokinetics, efficacy, and tolerability profiles facilitates the choice of appropriate antiseizure medication therapy for patients with epilepsy. Rational antiseizure medication combinations should avoid antiseizure medications with unfavorable pharmacokinetic interactions or pharmacodynamic interactions related to mechanism of action.
- |||||||||| Review, Journal: First Seizures, Acute Repetitive Seizures, and Status Epilepticus. (Pubmed Central) - Feb 3, 2025
First-phase treatment for convulsive established status epilepticus is the immediate administration of full doses of benzodiazepines. Second-phase treatment for convulsive established status epilepticus is a full loading dose of IV fosphenytoin, levetiracetam, valproic acid, or if necessary, phenobarbital.
- |||||||||| Review, Journal: Strategies to innovate emergency care of status epilepticus. (Pubmed Central) - Feb 2, 2025
Although three different benzodiazepines, diazepam, lorazepam and midazolam terminate early SE, midazolam is preferred...Interestingly, children treated with fosphenytoin were more likely to require intubation than those treated with valproic acid or levetiracetam. Better therapies are needed for the treatment established SE, because all three drugs were effective in less than 50
- |||||||||| levetiracetam / Generic mfg.
Journal: Valproate-Induced Hyperammonemic Encephalopathy Successfully Treated With Levocarnitine in an Elderly Patient Without Liver Dysfunction. (Pubmed Central) - Jan 30, 2025
Discontinuation of valproate, continuation of levetiracetam, and initiation of levocarnitine supplementation and branched-chain amino acid infusion resulted in a durable resolution of symptoms. This case underscores the importance of promptly considering valproate-induced hyperammonemic encephalopathy due to carnitine depletion in patients on long-term valproate therapy who develop acute encephalopathy and initiating levocarnitine treatment for effective management.
- |||||||||| Review, Journal: Management of brain tumour related epilepsy (BTRE): a narrative review and therapy recommendations. (Pubmed Central) - Jan 27, 2025
Vagus Nerve Stimulation has been used with partial success. The review highlights the relative dearth of high-quality evidence for the management of BTRE and provides a framework for further studies aiming to improve seizure control, quality of life, and indications for ASMs.KEY POINTSOffer levetiracetam or lamotrigine to all patients with primary or metastatic brain tumours who have seizure(s), irrespective of whether these are partial or generalised.ASM withdrawal for patients in remission is not recommended due to high rates of seizure recurrence.ASM prophylaxis is not generally recommended in the management of seizure-na
- |||||||||| Trial completion date, Trial primary completion date: Antiseizure Medication in Seizure Networks at Early Acute Brain Injury (clinicaltrials.gov) - Jan 24, 2025
P4, N=54, Recruiting,
The review highlights the relative dearth of high-quality evidence for the management of BTRE and provides a framework for further studies aiming to improve seizure control, quality of life, and indications for ASMs.KEY POINTSOffer levetiracetam or lamotrigine to all patients with primary or metastatic brain tumours who have seizure(s), irrespective of whether these are partial or generalised.ASM withdrawal for patients in remission is not recommended due to high rates of seizure recurrence.ASM prophylaxis is not generally recommended in the management of seizure-na Trial completion date: Feb 2025 --> Aug 2025 | Trial primary completion date: Nov 2024 --> May 2025
- |||||||||| levetiracetam / Generic mfg., methadone / Generic mfg.
Journal: Coma and confirmed epileptiform activity induced by Amanita pantherina poisoning. (Pubmed Central) - Jan 18, 2025
Gastrointestinal decontamination may be the only therapy for reducing toxins absorption and clinical severity. Our patient had acute severe neurological effects lasted many days, but she completely recovered with intensive treatment and levetiracetam administration.
- |||||||||| praziquantel / Generic mfg., levetiracetam / Generic mfg.
Journal: A Neurocysticercosis Case from Timor-Leste, A Previously Unidentified Region of Human Taeniasis Endemicity. (Pubmed Central) - Jan 15, 2025
This case underscores the importance of increased clinical vigilance in patients from areas of nonendemicity and the challenges in managing neurocysticercosis because of its evolving nature. The global health initiatives aimed at enhancing disease surveillance for human taeniasis are crucial for refining our knowledge on neurocysticercosis.
- |||||||||| levetiracetam / Generic mfg., topiramate / Generic mfg.
Journal: Abdominal pain as a novel manifestation in children with PCDH19-related epilepsy: A case report. (Pubmed Central) - Jan 12, 2025
This report describes abdominal pain as a novel manifestation of PCDH19-related epilepsy and might expand its phenotypes spectrum. It also alerts us to perceive the abdominal pain characterized by seizures and early conduct EEG examination to clarify the nature of abdominal pain.
- |||||||||| levetiracetam / Generic mfg.
Biomarker, Journal: Biomarkers. (Pubmed Central) - Jan 12, 2025
LEV resulted in region-specific increases in HFOs in both NEAD and EAD. Thus, HFOs can function as a biomarker of hyperexcitability in AD; however, their contribution to the epileptic phenotype in AD requires further investigation.
- |||||||||| levetiracetam / Generic mfg., doxycycline / Generic mfg.
Journal: Developing Topics. (Pubmed Central) - Jan 12, 2025
Daily levetiracetam administration was not effective in significantly reducing disease severity. Future studies will examine the effect of orthogonal approaches, such as AAV encoded chemogenetics, and characterize downstream mediators of TDP-43 -induced hyperexcitability, which may serve as more potent and specific therapeutic targets.
- |||||||||| levetiracetam / Generic mfg., diazepam / Generic mfg.
Journal: Drug Development. (Pubmed Central) - Jan 12, 2025
EOAD-associated risk genes do not equally influence age-related seizure susceptibility or impact ASM efficacy; seizures in AD may require precision medicine interventions. Further ASM profiling focused on attenuating neuronal hyperexcitability may uncover novel disease-modifying strategies for AD.
- |||||||||| levetiracetam / Generic mfg.
Journal: Weighing the Risk of Seizure Control: A Case of Levetiracetam-Induced Rhabdomyolysis. (Pubmed Central) - Dec 23, 2024
Although rare, this case highlights the critical need to monitor CPK levels in patients who develop rhabdomyolysis symptoms after restarting levetiracetam therapy. We recommend considering discontinuation of levetiracetam if no other identifiable causes are found.
- |||||||||| levetiracetam / Generic mfg.
Review, Journal: Scoping review of drug dosing recommendations in sustained low-efficiency dialysis. (Pubmed Central) - Dec 20, 2024
Four drug groups including beta-lactam antibiotics, non-beta-lactam antibiotics, antifungals, and levetiracetam were identified...Larger studies are needed to more accurately determine how to appropriately dose medications in SLED. Therapeutic drug monitoring should be used in all patients on SLED when available.
- |||||||||| levetiracetam / Generic mfg., carbamazepine / Generic mfg., oxcarbazepine / Generic mfg.
Retrospective data, Journal: Effects of valproic acid, levetiracetam, carbamazepine, and oxcarbazepine on thyroid function tests in children. (Pubmed Central) - Dec 19, 2024
Despite significant changes in thyroid hormone levels with valproic acid, carbamazepine, and oxcarbazepine treatment, no significant clinical findings were observed. Additionally, no effect of levetiracetam on thyroid function tests was detected.
- |||||||||| levetiracetam / Generic mfg.
Review, Journal: Intraventricular Glioblastoma in a Neonate: A Case Report and Literature Review. (Pubmed Central) - Dec 18, 2024
The 10-year postoperative follow-up revealed global developmental delay and seizures, which were controlled with levetiracetam...Histopathological examination is necessary to establish the diagnosis and predict the outcome. Despite the poor prognosis associated with intraventricular GBM, our patient demonstrated long-term survival and remained free of recurrence throughout the 10-year follow-up period after surgical excision.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma, Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Kineret (anakinra) / SOBI
Trial completion date, Trial primary completion date: Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants (clinicaltrials.gov) - Dec 18, 2024
P=N/A, N=1600, Recruiting,
Despite the poor prognosis associated with intraventricular GBM, our patient demonstrated long-term survival and remained free of recurrence throughout the 10-year follow-up period after surgical excision. Trial completion date: Jul 2026 --> Jul 2027 | Trial primary completion date: Sep 2024 --> Jul 2026
- |||||||||| levetiracetam / Generic mfg.
Review, Journal: The Oxidative Stress in Epilepsy-Focus on Melatonin. (Pubmed Central) - Dec 17, 2024
Generally, antiseizure medications reduce oxidative stress, although the data on levetiracetam are ambiguous...The anticonvulsant activity of exogenous melatonin may involve GABA-mediated inhibition, while endogenous melatonin may act as a proconvulsant due to a decrease in the brain dopaminergic transmission. Antioxidants, including melatonin, may be considered as adjuvants in the therapy of epilepsy and melatonin, in addition, in patients with epilepsy suffering from sleep disorders.
- |||||||||| phenytoin / Generic mfg.
Journal: The Phenytoin Ataxia Enigma Unveiled ''A Case Report''. (Pubmed Central) - Dec 12, 2024
Case: Herein, we present a case report of a 16-year-old Asian patient with a past history of epilepsy that was admitted to a tertiary care hospital due to the development of ataxia, giddiness, and vomiting when taking Phenytoin in addition to Oxcarbazepine, Clobazam, and Levetiracetam to treat seizures...Thus, the Phenytoin drug was discontinued in the patient gradually and he was continued on clobazam, oxcarbazepine, and brivaracetam which led to reversal of the ADR in the patient...Given the scarcity of ataxia cases caused by Phenytoin, awareness is lacking within the scientific community. Our aim is to provide insights to promote better monitoring and patient-centered treatment outcomes for epileptic patients.
- |||||||||| brivaracetam / Generic mfg.
Retrospective data, Journal, Monotherapy: BRIVA-ONE study: 12-month outcomes of brivaracetam monotherapy in clinical practice. (Pubmed Central) - Dec 11, 2024
In our study, monotherapy with BRV reduced seizures in patients who had not received other treatments and in patients who switched from a previous treatment to BRV monotherapy. BRV was well tolerated and also effective in sensitive patients (i.e., the elderly and those who had epilepsy caused by a brain tumor or a brain injury).
|
